Hikma is a pharmaceutical company founded in 1978 by Samih Darwazah in Amman, Jordan; now London-listed, it centers on affordable medicine supply to the Middle East and North Africa (MENA). It holds local manufacturing, participates in government tenders to secure supply to the public sector, and is building injectable plants in Algeria and Morocco to widen access. It has a 40-year partnership with the IFC (International Finance Corporation), and in 2025 a $250M financing agreement strengthened MENA access and local production. With Celltrion it introduces six biosimilars (affordable alternatives to costly biologics) across allergy, ophthalmology, immunology and oncology to MENA. In 2025 it set out a clear access-to-medicine strategy and says it treated over 220 million patients worldwide.
●●○ medium
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
Hikma Pharmaceuticals: Affordable medicines for MENA—Jordan-born, reaching 220 million patients. The letter is B; certainty is medium. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)
Main narrative
One person’s story (N1)
+ A single story
Patients in MENA who could not reach costly biologics or cancer/immune drugs. Through local production and biosimilar introduction, Hikma delivers affordable treatment. The benefit appears as a collective: in 2025 it says it treated over 220 million patients worldwide.
Source nature: P1 First-party / independent (IFC). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- Building injectable plants in Algeria and Morocco to widen MENA supply; introducing six biosimilars to MENA with Celltrion.P1 First-party / Hikma
− effects (confirmed)
- No confirmed −.
- A listed, for-profit pharmaceutical company (large US-business weighting)
- general debates over generic pricing and quality
- access metrics are partly self-reported.
- Quantifying MENA access; spreading biosimilars; expanding local production (Algeria/Morocco); maintaining quality and regulatory compliance.
A second look
The plus is affordable access to medicines for MENA patients (People), backed by the 40-year IFC partnership, local production, the 220-million figure, and Access to Medicine Foundation ratings. But it is a listed, for-profit pharmaceutical company whose main business is generics/injectables in the US and MENA, with a large US weighting, and the general debates over generic pricing and quality. Recognizing the genuine access plus, B/medium.
Sources
How to read this assessment
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the narrative an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top